Literature DB >> 25025016

Long-term hematological response in a patient with 5q- syndrome after suspension of lenalidomide therapy and further improvement with deferasirox therapy.

Pasquale Niscola1, Andrea Tendas1, Laura Scaramucci1, Roberta Merola2, Gianfranco Catalano1, Paolo de Fabritiis1.   

Abstract

Entities:  

Year:  2014        PMID： 25025016      PMCID： PMC4090335          DOI： 10.5045/br.2014.49.2.130

Source DB:  PubMed          Journal:  Blood Res        ISSN： 2287-979X


× No keyword cloud information.
  10 in total

1.  Haematological improvement as a beneficial effect during deferasirox treatment in transfusion-dependent patients with myelodysplastic syndrome.

Authors:  Matteo Molica; Adriano Salaroli; Giuliana Alimena; Massimo Breccia
Journal:  Blood Transfus       Date:  2013-04-15       Impact factor: 3.443

2.  Erythroid but not cytogenetic response in a case with 5q- syndrome: a delayed effect of lenalidomide or a consequence of deferasirox treatment?

Authors:  Ernesto Vigna; Anna Grazia Recchia; Maria Cuzzola; Lucio Morabito; Massimo Gentile; Fortunato Morabito
Journal:  Leuk Lymphoma       Date:  2013-09-09

3.  Very short-term lenalidomide treatment associated with durable resolution of anemia in a patient with myelodysplastic syndrome with chromosome 5q deletion.

Authors:  Laura Cannella; Roberto Latagliata; Massimo Breccia; Ida Carmosino; Giuseppina Loglisci; Paola Volpicelli; Antonietta Ferretti; Michelina Santopietro; Federico Vozella; Corrado Girmenia; Mariella Cuzzola; Esther Natalie Oliva; Giuliana Alimena
Journal:  Ann Hematol       Date:  2011-05-28       Impact factor: 3.673

4.  Unexpected erythroid and cytogenetic responses after discontinuation of a short course of lenalidomide as a result of severe skin rash in a patient with 5q syndrome.

Authors:  Massimo Breccia; Laura Cannella; Roberto Latagliata; Giuseppina Loglisci; Adriano Salaroli; Michelina Santopietro; Esther N Oliva; Giuliana Alimena
Journal:  J Clin Oncol       Date:  2011-02-28       Impact factor: 44.544

5.  A review of anemia as a cardiovascular risk factor in patients with myelodysplastic syndromes.

Authors:  Esther N Oliva; Carina Schey; Adam S Hutchings
Journal:  Am J Blood Res       Date:  2011-09-10

6.  International scoring system for evaluating prognosis in myelodysplastic syndromes.

Authors:  P Greenberg; C Cox; M M LeBeau; P Fenaux; P Morel; G Sanz; M Sanz; T Vallespi; T Hamblin; D Oscier; K Ohyashiki; K Toyama; C Aul; G Mufti; J Bennett
Journal:  Blood       Date:  1997-03-15       Impact factor: 22.113

Review 7.  Management of hematological malignancies in patients affected by renal failure.

Authors:  Pasquale Niscola; Gisella Vischini; Andrea Tendas; Laura Scaramucci; Marco Giovannini; Francesco Bondanini; Claudio Romani; Gregorio Antonio Brunetti; Claudio Cartoni; Luca Cupelli; Michele Ferrannini; Alessio Perrotti; Giovanni Del Poeta; Roberto Palumbo; Paolo de Fabritiis
Journal:  Expert Rev Anticancer Ther       Date:  2011-03       Impact factor: 4.512

8.  Hematologic responses to deferasirox therapy in transfusion-dependent patients with myelodysplastic syndromes.

Authors:  Norbert Gattermann; Carlo Finelli; Matteo Della Porta; Pierre Fenaux; Michael Stadler; Agnes Guerci-Bresler; Mathias Schmid; Kerry Taylor; Dominique Vassilieff; Dany Habr; Andrea Marcellari; Bernard Roubert; Christian Rose
Journal:  Haematologica       Date:  2012-03-14       Impact factor: 9.941

9.  Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes.

Authors:  Luca Malcovati; Ulrich Germing; Andrea Kuendgen; Matteo G Della Porta; Cristiana Pascutto; Rosangela Invernizzi; Aristoteles Giagounidis; Barbara Hildebrandt; Paolo Bernasconi; Sabine Knipp; Corinna Strupp; Mario Lazzarino; Carlo Aul; Mario Cazzola
Journal:  J Clin Oncol       Date:  2007-08-10       Impact factor: 44.544

10.  Lenalidomide in the context of complex karyotype or interrupted treatment: case reviews of del(5q)MDS patients with unexpected responses.

Authors:  Aristoteles A N Giagounidis; Sabine Haase; Michael Heinsch; Gudrun Göhring; Brigitte Schlegelberger; Carlo Aul
Journal:  Ann Hematol       Date:  2006-11-17       Impact factor: 3.673
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.